Unspecified

It is a choleretic and anti-inflammatory drug that decomposes into nicotinamide and formaldehyde after entering the body. The former has a liver-protecting effect, while the latter has an antibacterial effect, and can inhibit infections caused by diplococci, staphylococci, enterococci and Escherichia coli in the bile duct and intestines.

Extract from the above information

This product is a proton pump inhibitor for gastric parietal cells. It is relatively stable under neutral and weakly acidic conditions and rapidly activated under strongly acidic conditions. Its pH-dependent activation characteristics make it more selective for H and K-ATPase. This product can specifically inhibit the H and K-ATPase on the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. Since H and K-ATPase are the last process of acid secretion in parietal cells, this product has a strong acid-suppressing ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basal gastric acid secretion that is not affected by choline or H2 receptor blockers. When used with other drugs, this product has the advantage of small drug interactions. This product is metabolized through the I system of the cytochrome P450 enzyme system in hepatocytes, and can also be metabolized through the II system. When used with other drugs that are metabolized by the P450 enzyme system, the metabolic pathway of this product can be carried out through the II enzyme system, which makes it less likely to have competitive effects on the drug-metabolizing enzyme system and reduce the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.

Extract from the above information